~ (@Michael-official) en getquin

2Lun·

Bavarian Nordic $BAVA (-0,35 %) has received an order for 440.000 doses of its vaccine against Mpox and smallpox from a European 🇪🇺 state, which will 2024 will be delivered in 2024.

By the end of next year, the company can deliver up to ten million doses, of which two million before the end of this year.

The production of the vaccine is already being ramped up before ramped up.

3 Comentarios

tims92@tims92

2Lun

Lauterbach is already very excited....

•

Oleg@ScorpionfromBW

2Lun

Yeah, I'm sure everyone is waiting for it with excitement. Just get the stuff in

•

Matzke@Matzke

2Lun

The vaccine market is very small. It has developed dynamically from 2010 (USD 25 billion) to 2020 (USD 50 billion). Biontech seems like a "one hit wonder" in this market. Didn't make any money before Corona and didn't make it after Corona (despite many billions in cash). The idea of personalized cancer vaccines remains. Bavarian Nordic earns money, expands the business with the money earned - also through acquisitions. As an investor, I like a growing company in a growth market better at the moment. If Biontech's cancer vaccines turn out to be a success, it would be a quantum leap in medicine. This technology will probably not be available before 2030, if at all.

••